CG Oncology, Inc. Common stock (CGON) is a publicly traded Healthcare sector company. As of May 21, 2026, CGON trades at $64.79 with a market cap of $5.55B and a P/E ratio of -27.62. CGON moved +2.37% today. Year to date, CGON is +61.74%; over the trailing twelve months it is +143.82%. Its 52-week range spans $14.80 to $75.50. Analyst consensus is strong buy with an average price target of $89.47. Rallies surfaces CGON's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
CG Oncology rises as traders price in near-term Phase 3 PIVOT-006 data and target hikes: CG Oncology shares are higher as investors position ahead of multiple first-half 2026 clinical readouts for its lead bladder-cancer candidate, cretostimogene, including Phase 3 PIVOT-006 topline data. Recent analyst price-target hikes into the $75–$100 range have also supported momentum in the stock.
| Metric | Value |
|---|---|
| Price | $64.79 |
| Market Cap | $5.55B |
| P/E Ratio | -27.62 |
| EPS | $-2.33 |
| Dividend Yield | 0.00% |
| 52-Week High | $75.50 |
| 52-Week Low | $14.80 |
| Volume | 666.18K |
| Avg Volume | 0 |
| Revenue (TTM) | $5.07M |
| Net Income | $-186.75M |
| Gross Margin | 0.00% |
13 analysts cover CGON: 0 strong buy, 13 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $89.47.